FLT3 and acute myeloid leukemia: This finding is in line with clinical studies showing that midostaurin, a FLT3 inhibitor, improved 5-year event-free survival and overall survivals in FLT3-ITD-positive AML patients when administered in combination with standard chemotherapy [273].